Abstract
Mometasone furoate aqueous nasal spray (NS; Nasonex, Schering Corporation), is a synthetic corticosteroid approved for the prophylaxis and treatment of seasonal allergic rhinitis (SAR) and the treatment of perennial allergic rhinitis (PAR) in patients >or= 12 years of age, and for the treatment of SAR and PAR in children as young as 2 years of age. Studies demonstrate that mometasone furoate NS is a potent, clinically effective and well-tolerated intranasal corticosteroid with negligible systemic activity and which offers the convenience of once-daily dosing.
MeSH terms
-
Administration, Intranasal
-
Anti-Allergic Agents / administration & dosage
-
Anti-Allergic Agents / pharmacokinetics
-
Anti-Allergic Agents / therapeutic use*
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / pharmacokinetics
-
Anti-Inflammatory Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drug Administration Schedule
-
Glucocorticoids
-
Humans
-
Mometasone Furoate
-
Pregnadienediols / administration & dosage
-
Pregnadienediols / pharmacokinetics
-
Pregnadienediols / therapeutic use*
-
Rhinitis, Allergic, Perennial / drug therapy*
-
Rhinitis, Allergic, Perennial / prevention & control
-
Rhinitis, Allergic, Seasonal / drug therapy*
-
Rhinitis, Allergic, Seasonal / prevention & control
-
Sinusitis / drug therapy
Substances
-
Anti-Allergic Agents
-
Anti-Inflammatory Agents
-
Glucocorticoids
-
Pregnadienediols
-
Mometasone Furoate